Double Epigenetic Modulation of High-Dose Chemotherapy With Azacitidine and Vorinostat for Patients With Refractory or Poor-Risk Relapsed Lymphoma

BACKGROUND: More active high-dose chemotherapy (HDC) regimens are needed for refractory lymphomas. The authors previously combined infusional gemcitabine with busulfan and melphalan (Gem/Bu/Mel) pursuing DNA damage repair inhibition. Subsequently, they combined Gem/Bu/Mel with vorinostat, which faci...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Nieto, Yago, Valdez, Benigno C., Thall, Peter F., Jones, Roy B., Wei, Wei, Myers, Alan, Hosing, Chitra, Ahmed, Sairah, Popat, Uday, Shpall, Elizabeth J., Qazilbash, Muzaffar, Gulbis, Alison, Anderlini, Paolo, Shah, Nina, Bashir, Qaiser, Alousi, Amin, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Champlin, Richard, Andersson, Borje S.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4992444/
https://ncbi.nlm.nih.gov/pubmed/27203405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30100
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars